Cumulative proportion of ≥CIN2 among women with genotype-specific HPV persistence*5
MONITORING GENOTYPE-SPECIFIC HPV PERSISTENCE IS KEY TO IDENTIFYING YOUR PATIENTS AT MOST RISK FOR DEVELOPING CERVICAL DISEASE.1,2,5
HPV infection history and current HPV results are both critical when assessing the risk for cervical cancer and guiding patient management.1
THE BD ONCLARITY™ HPV ASSAY IS THE ONLY FDA-APPROVED ASSAY THAT HELPS TRACK GENOTYPE-SPECIFIC HPV PERSISTENCE USING EXTENDED GENOTYPING3,4
BD, the BD Logo, BD Onclarity™ are trademarks of Becton, Dickinson and Company or its affiliates. ©2022 BD. All rights reserved.
The BD Onclarity™ HPV Assay is an in vitro diagnostic medical device bearing a CE mark.